Saturday 17 October 2026
Export NEO’s income statement to Excel — free account
NeoGenomics, Inc.
NEO Healthcare Diagnostics & Research
NeoGenomics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $727.3 million, up 10.1% from fiscal 2024. In the quarter to June 2026, revenue grew 11.2%, EPS grew 105.7%, free cash flow fell 16.2% and total debt rose 10.9%, each against the same quarter a year earlier. Revenue growth for ten consecutive years.
16.65
0.60
−3.48%
Follow NEO
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
| (6.33%) | (11.56%) | (12.42%) | (12.99%) |
+8 more TTM periods Free account |
|
Piotroski F-Score |
5 | 4 | 4 | 4 | |
| (3.78%) | (6.73%) | (7.21%) | (7.52%) | ||
ROIC |
(4.20%) | (6.48%) | (7.11%) | (7.44%) | |
Return on Tangible Assets |
(14.55%) | (26.61%) | (28.98%) | (30.66%) | |
Average Days of Receivables |
83.55 | 81.92 | 79.91 | 79.93 | |
Free Cash Flow per Share |
(0.04) | (0.02) | (0.15) | (0.13) | |
Free Cash Flow |
(5.29) | (3.02) | (19.71) | (17.05) | |
Capital Expenditures |
(27.34) | (25.44) | (24.94) | (30.74) | |
| Other line items | |||||
Cash ROIC |
(0.40%) | (0.23%) | (1.47%) | (1.27%) | |
Accounts Receivable Turnover |
4.67 | 4.68 | 4.70 | 4.62 | |
Accounts Payable Turnover |
17.74 | 20.14 | 18.48 | 20.50 | |
Inventory Turnover |
14.02 | 14.23 | 14.93 | 15.15 | |
Average Days of Payables |
17.80 | 22.29 | 20.40 | 20.58 | |
Days of Inventory on Hand |
23.05 | 25.68 | 25.24 | 25.91 | |
Tax Rate |
(0.05) | (0.03) | (0.02) | 0.00 | |
Research and Development Expense of Revenue |
4.98% | 4.88% | 5.10% | 5.06% | |
Selling, General and Administrative Expense of Revenue |
46.86% | 48.80% | 50.23% | 51.38% | |
Share Based Compensation of Revenue |
4.72% | 5.39% | 5.68% | 5.87% | |
Interest Coverage |
(26.52) | (38.89) | (30.88) | (25.30) | |
Operating CF/Net income |
(0.42) | (0.23) | (0.05) | (0.12) | |
Depreciation/Fixed assets |
0.83 | 0.82 | 0.82 | 0.84 | |
Capex/Depreciation |
(0.41) | (0.37) | (0.36) | (0.43) | |
Revenue per Share |
5.91 | 5.78 | 5.68 | 5.52 | |
Operating CF per Share |
0.17 | 0.17 | 0.04 | 0.11 | |
Capex per Share |
(0.21) | (0.20) | (0.19) | (0.24) | |
Capex to Sales |
0.04 | 0.03 | 0.03 | 0.04 |
Columns are period end dates